Drug Profile
Ebvaciclib - Pfizer
Alternative Names: PF-06873600; PF-3600Latest Information Update: 03 Feb 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Piperidines; Pyridones; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 03 Feb 2023 Discontinued - Phase-I/II for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 03 Feb 2023 Discontinued - Phase-I/II for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO)
- 03 Feb 2023 Discontinued - Phase-I/II for Fallopian tube cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)